OTOwen Thomas

Owen Thomas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Owen Thomas has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Three-dimensional kinematic gait signatures of idiopathic normal pressure hydrocephalus: a biomechanical framework toward objective diagnosis

    by Richard Mills, Tobias Langheinrich, Liis Uiga, Katherine A. J. Daniels, Sean Maudsley-Barton, Mariam Riaz, Cliff Chen, Owen Thomas, Claire Atherton, Neil D. Reeves, et al.

    Background: Idiopathic Normal Pressure Hydrocephalus (iNPH) is a leading cause of reversible gait disturbance in older adults, yet diagnosis and treatment selection remain limited by low-sensitivity clinical assessments. Conventional tests such as the 10-metre walk and Timed Up-and-Go capture overall performance but overlook the multidimensional, joint-level alterations that characterise iNPH gait. This study aimed to deliver the first comprehensive, three-dimensional (3D) biomechanical characterisation of iNPH gait to inform more objective diagnostic frameworks. Methods: Twenty-three participants with clinically diagnosed iNPH and eighteen age-matched healthy controls underwent baseline gait analysis (iNPH: pre tap test) consisting of overground walking using a 3D optoelectronic motion capture system with integrated force plates. Spatiotemporal parameters were compared using independent-samples t -tests, while continuous kinematic (i.e., joint angle) waveforms for the pelvis, hip, knee, and ankle were analysed using one-dimensional statistical parametric mapping (SPM). A binary logistic regression model was developed to classify participants as iNPH or healthy control. Results: Compared with controls, individuals with iNPH demonstrated markedly slower gait speed (–60%), shorter stride length (–52%), and greater stride width (+ 64%), each with large effect sizes (1.5–3.3; p < .001). SPM revealed multi-joint, phase-specific impairments in sagittal and frontal plane kinematics, including reduced pelvic obliquity, diminished hip flexion/extension and abduction, attenuated knee flexion during swing, and blunted ankle plantarflexion at push-off ( p < .05). These findings indicate impaired supraspinal coordination consistent with frontal-subcortical motor network dysfunction. Further, the statistical modelling achieved excellent discrimination between patients with iNPH and healthy controls. Due to short-stepped iNPH gait causing multiple consecutive steps on a single force plate, kinetics (i.e., ground reaction forces; joint moments) could not be analysed. Conclusions: This study suggests the first detailed biomechanical signatures of gait in iNPH, identifying spatiotemporal and joint-specific alterations that together define a central coordination deficit. Beyond confirming known gait slowing, these results delineate kinematic markers with translational potential as digital biomarkers for diagnosis and postoperative monitoring. By advancing gait analysis from simple bedside tests to detailed quantification, 3D motion capture offers a rigorous, reproducible framework that may improve diagnostic sensitivity in patients with iNPH. However, larger future studies should include clinically more heterogeneous cohorts and incorporate relevant disease mimics (e.g., Parkinson’s disease, progressive supranuclear palsy) to determine differentiation capabilities of the predictive modelling.

  • Open Access

    Blood-brain barrier dysfunction predicts cognitive trajectory after ischemic stroke

    by Lei Xue, Olivia A Jones, Lauren Drag, Kristy A. Zera, Li Zhu, Michael Mlynash, Natasha S. Carmichael, Chi-Hung Shu, Zuzanna Biesiada, David Seong, et al.

    Ischemic stroke doubles the risk of dementia. 1–4 Stroke severity and location affect cognition early, 5,6 but late dementia risk is not related to infarct characteristics, nor is it reduced by preventing additional strokes, 3,6,7 and its mechanism is unknown. We identified a plasma proteomic signature of chronic stroke that was consistent with blood-brain barrier (BBB) dysfunction, including a 58% decrease in plasma levels of platelet-derived growth factor B and downregulation of its pathway compared to healthy controls. During 2 years of follow-up, the stroke-specific proteome was accentuated in stroke survivors who subsequently declined in the processing speed/executive function cognitive domain. To test BBB function, we performed dynamic contrast-enhanced MRI 6-9 months after stroke in an additional cohort and found 1.7-fold higher whole brain BBB leakage compared to controls. Finally, we compared autopsy tissue from people with infarcts and dementia at death to those with infarcts and no dementia. Those who died with dementia had dramatic loss of vascular mural cell coverage compared to those without dementia (median 0.7% vs. 27%). Thus, our proteomic, functional, and structural data implicate chronic BBB dysfunction in cognitive decline late after stroke, revealing potential proteomic and imaging biomarkers and, importantly, a novel target for intervention.


  • Open Access

    Randomised controlled trial of simvastatin treatment for autism in young children with neurofibromatosis type 1 (SANTA)

    by SANTA Consortium, Stavros Stivaros, Shruti Garg, Maria Tziraki, Ying Cai, Owen Thomas, Joseph Mellor, Andrew A. Morris, Carly Jim, Karolina Szumanska-Ryt, et al.

    Neurofibromatosis 1 (NF1) is a monogenic model for syndromic autism. Statins rescue the social and cognitive phenotype in animal knockout models, but translational trials with subjects > 8 years using cognition/behaviour outcomes have shown mixed results. This trial breaks new ground by studying statin effects for the first time in younger children with NF1 and co-morbid autism and by using multiparametric imaging outcomes. A single-site triple-blind RCT of simvastatin vs. placebo was done. Assessment (baseline and 12-week endpoint) included peripheral MAPK assay, awake magnetic resonance imaging spectroscopy (MRS; GABA and glutamate+glutamine (Glx)), arterial spin labelling (ASL), apparent diffusion coefficient (ADC), resting state functional MRI, and autism behavioural outcomes (Aberrant Behaviour Checklist and Clinical Global Impression). Thirty subjects had a mean age of 8.1 years (SD 1.8). Simvastatin was well tolerated. The amount of imaging data varied by test. Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12) = − 2.12, p = .055), GABA/Glx ratio (t(12) = − 2.78, p = .016), and reduced grey nuclei Glx (ANCOVA p < 0.05, Mann-Whitney p < 0.01); (ii) increased ASL perfusion in ventral diencephalon (Mann-Whitney p < 0.01); and (iii) decreased ADC in cingulate gyrus (Mann-Whitney p < 0.01). Machine-learning classification of imaging outcomes achieved 79% (p < .05) accuracy differentiating groups at endpoint against chance level (64%, p = 0.25) at baseline. Three of 12 (25%) simvastatin cases compared to none in placebo met ‘clinical responder’ criteria for behavioural outcome. We show feasibility of peripheral MAPK assay and autism symptom measurement, but the study was not powered to test effectiveness. Multiparametric imaging suggests possible simvastatin effects in brain areas previously associated with NF1 pathophysiology and the social brain network. EU Clinical Trial Register (EudraCT) 2012-005742-38 ( www.clinicaltrialsregister.eu )